Pharmacology:萝卜硫素可逆转氧化应激对成骨细胞活性和矿化的抑制作用

2019-07-31 sunshine 译 MedSci原创

Sulforaphane(SFN)被认为是一种抗氧化剂,但对缺氧处理的成骨细胞的生物学作用仍不清楚。因此,本研究旨在探究SFN对缺氧时成骨细胞活性和矿化的影响。在有或没有SFN的情况下用低氧处理成骨细胞,并用胱天蛋白酶3活性测定试剂盒和流式细胞仪测定细胞凋亡。用DCFH-DA测量活性氧(ROS)的水平。通过邻苯二甲醛荧光测定法测定谷胱甘肽(GSH)和谷胱甘肽二硫化物的水平。通过茜素红染色和碱性磷酸

Sulforaphane(SFN)被认为是一种抗氧化剂,但对缺氧处理的成骨细胞的生物学作用仍不清楚。因此,本研究旨在探究SFN对缺氧时成骨细胞活性和矿化的影响。

在有或没有SFN的情况下用低氧处理成骨细胞,并用胱天蛋白酶3活性测定试剂盒和流式细胞仪测定细胞凋亡。用DCFH-DA测量活性氧(ROS)的水平。通过邻苯二甲醛荧光测定法测定谷胱甘肽(GSH)和谷胱甘肽二硫化物的水平。通过茜素红染色和碱性磷酸酶(ALP)染色检测成骨细胞的矿化,并通过蛋白质印迹检查相对蛋白质水平。

结果表明,SFN可以降低成骨细胞中缺氧介导的细胞凋亡和ROS水平。SFN的利用提高了缺氧对成骨细胞矿化的抑制作用。另外,SFN减轻缺氧的效果将是成骨细胞活性的增加。

总之,这些发现阐明了SFN对缺氧处理的骨生成的影响,并将有助于确定保护骨骼健康的新型治疗策略。

原始出处:

Chen Q, Wu S, et al., The Effect of Sulforaphane on the Activity and Mineralization of Osteoblasts under Oxidative Stress. Pharmacology. 2019 Jul 30:1-10. doi: 10.1159/000500846. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1996306, encodeId=858c199630612, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Jan 04 13:18:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788370, encodeId=0ef91e883703f, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Aug 06 07:18:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721332, encodeId=f9e01e2133253, content=<a href='/topic/show?id=0143e3298c3' target=_blank style='color:#2F92EE;'>#矿化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73298, encryptionId=0143e3298c3, topicName=矿化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a5532986439, createdName=yahu, createdTime=Wed Aug 07 16:18:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635458, encodeId=f9ac1635458cd, content=<a href='/topic/show?id=b099549160a' target=_blank style='color:#2F92EE;'>#抑制作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54916, encryptionId=b099549160a, topicName=抑制作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd322475383, createdName=124987a0m73(暂无昵称), createdTime=Sat Dec 21 08:18:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788663, encodeId=5cb01e886631f, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Thu Oct 31 16:18:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787624, encodeId=b59b1e876241f, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jun 21 16:18:00 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352193, encodeId=22c51352193db, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 02 09:18:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445290, encodeId=3079144529082, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Fri Aug 02 09:18:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495179, encodeId=191a14951e91c, content=<a href='/topic/show?id=3c0b10182102' target=_blank style='color:#2F92EE;'>#骨细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101821, encryptionId=3c0b10182102, topicName=骨细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=723c9147696, createdName=jj000004, createdTime=Fri Aug 02 09:18:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908555, encodeId=ad8d190855599, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Jan 03 23:18:00 CST 2020, time=2020-01-03, status=1, ipAttribution=)]
    2020-01-04 yb6560
  2. [GetPortalCommentsPageByObjectIdResponse(id=1996306, encodeId=858c199630612, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Jan 04 13:18:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788370, encodeId=0ef91e883703f, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Aug 06 07:18:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721332, encodeId=f9e01e2133253, content=<a href='/topic/show?id=0143e3298c3' target=_blank style='color:#2F92EE;'>#矿化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73298, encryptionId=0143e3298c3, topicName=矿化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a5532986439, createdName=yahu, createdTime=Wed Aug 07 16:18:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635458, encodeId=f9ac1635458cd, content=<a href='/topic/show?id=b099549160a' target=_blank style='color:#2F92EE;'>#抑制作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54916, encryptionId=b099549160a, topicName=抑制作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd322475383, createdName=124987a0m73(暂无昵称), createdTime=Sat Dec 21 08:18:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788663, encodeId=5cb01e886631f, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Thu Oct 31 16:18:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787624, encodeId=b59b1e876241f, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jun 21 16:18:00 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352193, encodeId=22c51352193db, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 02 09:18:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445290, encodeId=3079144529082, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Fri Aug 02 09:18:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495179, encodeId=191a14951e91c, content=<a href='/topic/show?id=3c0b10182102' target=_blank style='color:#2F92EE;'>#骨细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101821, encryptionId=3c0b10182102, topicName=骨细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=723c9147696, createdName=jj000004, createdTime=Fri Aug 02 09:18:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908555, encodeId=ad8d190855599, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Jan 03 23:18:00 CST 2020, time=2020-01-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1996306, encodeId=858c199630612, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Jan 04 13:18:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788370, encodeId=0ef91e883703f, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Aug 06 07:18:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721332, encodeId=f9e01e2133253, content=<a href='/topic/show?id=0143e3298c3' target=_blank style='color:#2F92EE;'>#矿化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73298, encryptionId=0143e3298c3, topicName=矿化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a5532986439, createdName=yahu, createdTime=Wed Aug 07 16:18:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635458, encodeId=f9ac1635458cd, content=<a href='/topic/show?id=b099549160a' target=_blank style='color:#2F92EE;'>#抑制作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54916, encryptionId=b099549160a, topicName=抑制作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd322475383, createdName=124987a0m73(暂无昵称), createdTime=Sat Dec 21 08:18:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788663, encodeId=5cb01e886631f, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Thu Oct 31 16:18:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787624, encodeId=b59b1e876241f, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jun 21 16:18:00 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352193, encodeId=22c51352193db, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 02 09:18:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445290, encodeId=3079144529082, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Fri Aug 02 09:18:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495179, encodeId=191a14951e91c, content=<a href='/topic/show?id=3c0b10182102' target=_blank style='color:#2F92EE;'>#骨细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101821, encryptionId=3c0b10182102, topicName=骨细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=723c9147696, createdName=jj000004, createdTime=Fri Aug 02 09:18:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908555, encodeId=ad8d190855599, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Jan 03 23:18:00 CST 2020, time=2020-01-03, status=1, ipAttribution=)]
    2019-08-07 yahu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1996306, encodeId=858c199630612, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Jan 04 13:18:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788370, encodeId=0ef91e883703f, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Aug 06 07:18:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721332, encodeId=f9e01e2133253, content=<a href='/topic/show?id=0143e3298c3' target=_blank style='color:#2F92EE;'>#矿化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73298, encryptionId=0143e3298c3, topicName=矿化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a5532986439, createdName=yahu, createdTime=Wed Aug 07 16:18:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635458, encodeId=f9ac1635458cd, content=<a href='/topic/show?id=b099549160a' target=_blank style='color:#2F92EE;'>#抑制作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54916, encryptionId=b099549160a, topicName=抑制作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd322475383, createdName=124987a0m73(暂无昵称), createdTime=Sat Dec 21 08:18:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788663, encodeId=5cb01e886631f, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Thu Oct 31 16:18:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787624, encodeId=b59b1e876241f, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jun 21 16:18:00 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352193, encodeId=22c51352193db, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 02 09:18:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445290, encodeId=3079144529082, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Fri Aug 02 09:18:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495179, encodeId=191a14951e91c, content=<a href='/topic/show?id=3c0b10182102' target=_blank style='color:#2F92EE;'>#骨细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101821, encryptionId=3c0b10182102, topicName=骨细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=723c9147696, createdName=jj000004, createdTime=Fri Aug 02 09:18:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908555, encodeId=ad8d190855599, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Jan 03 23:18:00 CST 2020, time=2020-01-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1996306, encodeId=858c199630612, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Jan 04 13:18:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788370, encodeId=0ef91e883703f, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Aug 06 07:18:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721332, encodeId=f9e01e2133253, content=<a href='/topic/show?id=0143e3298c3' target=_blank style='color:#2F92EE;'>#矿化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73298, encryptionId=0143e3298c3, topicName=矿化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a5532986439, createdName=yahu, createdTime=Wed Aug 07 16:18:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635458, encodeId=f9ac1635458cd, content=<a href='/topic/show?id=b099549160a' target=_blank style='color:#2F92EE;'>#抑制作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54916, encryptionId=b099549160a, topicName=抑制作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd322475383, createdName=124987a0m73(暂无昵称), createdTime=Sat Dec 21 08:18:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788663, encodeId=5cb01e886631f, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Thu Oct 31 16:18:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787624, encodeId=b59b1e876241f, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jun 21 16:18:00 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352193, encodeId=22c51352193db, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 02 09:18:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445290, encodeId=3079144529082, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Fri Aug 02 09:18:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495179, encodeId=191a14951e91c, content=<a href='/topic/show?id=3c0b10182102' target=_blank style='color:#2F92EE;'>#骨细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101821, encryptionId=3c0b10182102, topicName=骨细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=723c9147696, createdName=jj000004, createdTime=Fri Aug 02 09:18:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908555, encodeId=ad8d190855599, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Jan 03 23:18:00 CST 2020, time=2020-01-03, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1996306, encodeId=858c199630612, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Jan 04 13:18:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788370, encodeId=0ef91e883703f, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Aug 06 07:18:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721332, encodeId=f9e01e2133253, content=<a href='/topic/show?id=0143e3298c3' target=_blank style='color:#2F92EE;'>#矿化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73298, encryptionId=0143e3298c3, topicName=矿化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a5532986439, createdName=yahu, createdTime=Wed Aug 07 16:18:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635458, encodeId=f9ac1635458cd, content=<a href='/topic/show?id=b099549160a' target=_blank style='color:#2F92EE;'>#抑制作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54916, encryptionId=b099549160a, topicName=抑制作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd322475383, createdName=124987a0m73(暂无昵称), createdTime=Sat Dec 21 08:18:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788663, encodeId=5cb01e886631f, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Thu Oct 31 16:18:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787624, encodeId=b59b1e876241f, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jun 21 16:18:00 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352193, encodeId=22c51352193db, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 02 09:18:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445290, encodeId=3079144529082, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Fri Aug 02 09:18:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495179, encodeId=191a14951e91c, content=<a href='/topic/show?id=3c0b10182102' target=_blank style='color:#2F92EE;'>#骨细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101821, encryptionId=3c0b10182102, topicName=骨细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=723c9147696, createdName=jj000004, createdTime=Fri Aug 02 09:18:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908555, encodeId=ad8d190855599, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Jan 03 23:18:00 CST 2020, time=2020-01-03, status=1, ipAttribution=)]
    2020-06-21 jj000001
  7. [GetPortalCommentsPageByObjectIdResponse(id=1996306, encodeId=858c199630612, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Jan 04 13:18:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788370, encodeId=0ef91e883703f, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Aug 06 07:18:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721332, encodeId=f9e01e2133253, content=<a href='/topic/show?id=0143e3298c3' target=_blank style='color:#2F92EE;'>#矿化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73298, encryptionId=0143e3298c3, topicName=矿化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a5532986439, createdName=yahu, createdTime=Wed Aug 07 16:18:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635458, encodeId=f9ac1635458cd, content=<a href='/topic/show?id=b099549160a' target=_blank style='color:#2F92EE;'>#抑制作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54916, encryptionId=b099549160a, topicName=抑制作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd322475383, createdName=124987a0m73(暂无昵称), createdTime=Sat Dec 21 08:18:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788663, encodeId=5cb01e886631f, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Thu Oct 31 16:18:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787624, encodeId=b59b1e876241f, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jun 21 16:18:00 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352193, encodeId=22c51352193db, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 02 09:18:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445290, encodeId=3079144529082, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Fri Aug 02 09:18:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495179, encodeId=191a14951e91c, content=<a href='/topic/show?id=3c0b10182102' target=_blank style='color:#2F92EE;'>#骨细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101821, encryptionId=3c0b10182102, topicName=骨细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=723c9147696, createdName=jj000004, createdTime=Fri Aug 02 09:18:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908555, encodeId=ad8d190855599, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Jan 03 23:18:00 CST 2020, time=2020-01-03, status=1, ipAttribution=)]
    2019-08-02 zhaojie88
  8. [GetPortalCommentsPageByObjectIdResponse(id=1996306, encodeId=858c199630612, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Jan 04 13:18:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788370, encodeId=0ef91e883703f, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Aug 06 07:18:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721332, encodeId=f9e01e2133253, content=<a href='/topic/show?id=0143e3298c3' target=_blank style='color:#2F92EE;'>#矿化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73298, encryptionId=0143e3298c3, topicName=矿化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a5532986439, createdName=yahu, createdTime=Wed Aug 07 16:18:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635458, encodeId=f9ac1635458cd, content=<a href='/topic/show?id=b099549160a' target=_blank style='color:#2F92EE;'>#抑制作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54916, encryptionId=b099549160a, topicName=抑制作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd322475383, createdName=124987a0m73(暂无昵称), createdTime=Sat Dec 21 08:18:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788663, encodeId=5cb01e886631f, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Thu Oct 31 16:18:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787624, encodeId=b59b1e876241f, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jun 21 16:18:00 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352193, encodeId=22c51352193db, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 02 09:18:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445290, encodeId=3079144529082, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Fri Aug 02 09:18:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495179, encodeId=191a14951e91c, content=<a href='/topic/show?id=3c0b10182102' target=_blank style='color:#2F92EE;'>#骨细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101821, encryptionId=3c0b10182102, topicName=骨细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=723c9147696, createdName=jj000004, createdTime=Fri Aug 02 09:18:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908555, encodeId=ad8d190855599, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Jan 03 23:18:00 CST 2020, time=2020-01-03, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1996306, encodeId=858c199630612, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Jan 04 13:18:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788370, encodeId=0ef91e883703f, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Aug 06 07:18:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721332, encodeId=f9e01e2133253, content=<a href='/topic/show?id=0143e3298c3' target=_blank style='color:#2F92EE;'>#矿化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73298, encryptionId=0143e3298c3, topicName=矿化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a5532986439, createdName=yahu, createdTime=Wed Aug 07 16:18:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635458, encodeId=f9ac1635458cd, content=<a href='/topic/show?id=b099549160a' target=_blank style='color:#2F92EE;'>#抑制作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54916, encryptionId=b099549160a, topicName=抑制作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd322475383, createdName=124987a0m73(暂无昵称), createdTime=Sat Dec 21 08:18:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788663, encodeId=5cb01e886631f, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Thu Oct 31 16:18:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787624, encodeId=b59b1e876241f, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jun 21 16:18:00 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352193, encodeId=22c51352193db, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 02 09:18:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445290, encodeId=3079144529082, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Fri Aug 02 09:18:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495179, encodeId=191a14951e91c, content=<a href='/topic/show?id=3c0b10182102' target=_blank style='color:#2F92EE;'>#骨细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101821, encryptionId=3c0b10182102, topicName=骨细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=723c9147696, createdName=jj000004, createdTime=Fri Aug 02 09:18:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908555, encodeId=ad8d190855599, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Jan 03 23:18:00 CST 2020, time=2020-01-03, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1996306, encodeId=858c199630612, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Jan 04 13:18:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788370, encodeId=0ef91e883703f, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Aug 06 07:18:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721332, encodeId=f9e01e2133253, content=<a href='/topic/show?id=0143e3298c3' target=_blank style='color:#2F92EE;'>#矿化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73298, encryptionId=0143e3298c3, topicName=矿化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a5532986439, createdName=yahu, createdTime=Wed Aug 07 16:18:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635458, encodeId=f9ac1635458cd, content=<a href='/topic/show?id=b099549160a' target=_blank style='color:#2F92EE;'>#抑制作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54916, encryptionId=b099549160a, topicName=抑制作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd322475383, createdName=124987a0m73(暂无昵称), createdTime=Sat Dec 21 08:18:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788663, encodeId=5cb01e886631f, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Thu Oct 31 16:18:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787624, encodeId=b59b1e876241f, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jun 21 16:18:00 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352193, encodeId=22c51352193db, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 02 09:18:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445290, encodeId=3079144529082, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Fri Aug 02 09:18:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495179, encodeId=191a14951e91c, content=<a href='/topic/show?id=3c0b10182102' target=_blank style='color:#2F92EE;'>#骨细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101821, encryptionId=3c0b10182102, topicName=骨细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=723c9147696, createdName=jj000004, createdTime=Fri Aug 02 09:18:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908555, encodeId=ad8d190855599, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Jan 03 23:18:00 CST 2020, time=2020-01-03, status=1, ipAttribution=)]